{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:23:28Z","timestamp":1791195808103,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-018-1020-5","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T08:04:54Z","timestamp":1548921894000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease"],"prefix":"10.1007","volume":"79","author":[{"given":"Ali","family":"Canbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Peter","family":"Sowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"1020_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol Baltim Md. 2016;64:73\u201384.","journal-title":"Hepatol Baltim Md"},{"key":"1020_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"1020_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221\u201331.","journal-title":"N Engl J Med"},{"key":"1020_CR5","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatol Baltim Md. 2010;52:1836\u201346.","journal-title":"Hepatol Baltim Md"},{"issue":"131","key":"1020_CR6","first-page":"2701","volume":"2017","author":"A Gastaldelli","year":"1979","unstructured":"Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci Lond Engl. 1979;2017(131):2701\u20134.","journal-title":"Clin Sci Lond Engl"},{"key":"1020_CR7","doi-asserted-by":"publisher","first-page":"15430","DOI":"10.1073\/pnas.0904944106","volume":"106","author":"E Fabbrini","year":"2009","unstructured":"Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009;106:15430\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1020_CR8","doi-asserted-by":"crossref","unstructured":"Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-J\u00e4rvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2010;42:320\u201330.","DOI":"10.1016\/j.dld.2010.01.016"},{"issue":"513\u2013525","key":"1020_CR9","first-page":"e0","volume":"151","author":"A Teufel","year":"2016","unstructured":"Teufel A, Itzel T, Erhart W, Brosch M, Wang XY, Kim YO, et al. Comparison of gene expression patterns between mouse models\u00a0of nonalcoholic fatty liver disease and liver tissues\u00a0from patients. Gastroenterology. 2016;151(513\u2013525):e0.","journal-title":"Gastroenterology"},{"key":"1020_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cld.708","volume":"11","author":"N Alkhouri","year":"2018","unstructured":"Alkhouri N, Scott A. An update on the pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications. Clin Liver Dis. 2018;11:82\u20136.","journal-title":"Clin Liver Dis"},{"issue":"3","key":"1020_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jceh.2018.05.004","volume":"8","author":"RF Butterworth","year":"2018","unstructured":"Butterworth RF, Kircheis G, Hilger N, McPhail MJW. Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: systematic review and meta-analysis of randomized controlled trials. J Clin Exp Hepatol. 2018;8(3):301\u201313.","journal-title":"J Clin Exp Hepatol."},{"key":"1020_CR12","doi-asserted-by":"publisher","first-page":"e0173914","DOI":"10.1371\/journal.pone.0173914","volume":"12","author":"V Guti\u00e9rrez-de-Juan","year":"2017","unstructured":"Guti\u00e9rrez-de-Juan V, L\u00f3pez de Davalillo S, Fern\u00e1ndez-Ramos D, Barbier-Torres L, Zubiete-Franco I, Fern\u00e1ndez-Tussy P, et al. A morphological method for ammonia detection in liver. PLoS One. 2017;12:e0173914.","journal-title":"PLoS One"},{"key":"1020_CR13","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.23500","volume":"51","author":"P Jepsen","year":"2010","unstructured":"Jepsen P, Ott P, Andersen PK, S\u00f8rensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatol Baltim Md. 2010;51:1675\u201382.","journal-title":"Hepatol Baltim Md"},{"key":"1020_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.mehy.2018.02.010","volume":"113","author":"KL Thomsen","year":"2018","unstructured":"Thomsen KL, De Chiara F, Rombouts K, Vilstrup H, Andreola F, Mookerjee RP, et al. Ammonia: a novel target for the treatment of non-alcoholic steatohepatitis. Med Hypotheses. 2018;113:91\u20137.","journal-title":"Med Hypotheses"},{"key":"1020_CR15","unstructured":"Butterworth RF, Canbay A. Hepatoprotection by l-ornithine l-aspartate in non-alcoholic fatty liver disease. Dig Dis Basel Switz. 2018;17:1\u20136."},{"key":"1020_CR16","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jceh.2017.01.009","volume":"7","author":"Y Pasha","year":"2017","unstructured":"Pasha Y, Leech R, Violante IR, Cook N, Crossey MME, Taylor-Robinson SD. The brain-muscle axis in minimal hepatic encephalopathy (MHE): a placebo-controlled, longitudinal double-blind trial with l-Ornithine l-Aspartate (LOLA)\u2014preliminary results. J Clin Exp Hepatol. 2017;7:S5\u20136.","journal-title":"J Clin Exp Hepatol"},{"key":"1020_CR17","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1124\/dmd.115.063388","volume":"43","author":"K Kus","year":"2015","unstructured":"Kus K, Walczak M, Maslak E, Zakrzewska A, Gonciarz-Dytman A, Zabielski P, et al. Hepatoselective nitric oxide (NO) donors, V-PYRRO\/NO and V-PROLI\/NO, in nonalcoholic fatty liver disease: a comparison of antisteatotic effects with the biotransformation and pharmacokinetics. Drug Metab Dispos Biol Fate Chem. 2015;43:1028\u201336.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"1020_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11011-011-9269-3","volume":"27","author":"V Felipo","year":"2012","unstructured":"Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres ML, Civera M, et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis. 2012;27:51\u20138.","journal-title":"Metab Brain Dis"},{"key":"1020_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0014-5793(96)01344-0","volume":"399","author":"M Tomomura","year":"1996","unstructured":"Tomomura M, Tomomura A, Dewan MA, Saheki T. Long-chain fatty acids suppress the induction of urea cycle enzyme genes by glucocorticoid action. FEBS Lett. 1996;399:310\u20132.","journal-title":"FEBS Lett"},{"key":"1020_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2362.1988.tb01053.x","volume":"18","author":"S Kaiser","year":"1988","unstructured":"Kaiser S, Gerok W, H\u00e4ussinger D. Ammonia and glutamine metabolism in human liver slices: new aspects on the pathogenesis of hyperammonaemia in chronic liver disease. Eur J Clin Invest. 1988;18:535\u201342.","journal-title":"Eur J Clin Invest"},{"key":"1020_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jhep.2018.06.023","volume":"69","author":"F Chiara De","year":"2018","unstructured":"De Chiara F, Heeb\u00f8ll S, Marrone G, Montoliu C, Hamilton-Dutoit S, Ferrandez A, et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J Hepatol. 2018;69:905\u201315.","journal-title":"J Hepatol"},{"key":"1020_CR22","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.29107","volume":"65","author":"A Kumar","year":"2017","unstructured":"Kumar A, Davuluri G, Silva RNE, Engelen MPKJ, Ten Have GAM, Prayson R, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatol Baltim Md. 2017;65:2045\u201358.","journal-title":"Hepatol Baltim Md"},{"key":"1020_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1023\/A:1020613314572","volume":"13","author":"C Rose","year":"1998","unstructured":"Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, et al. l-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998;13:147\u201357.","journal-title":"Metab Brain Dis"},{"key":"1020_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3892\/etm.2013.1434","volume":"7","author":"Z Lin","year":"2014","unstructured":"Lin Z, Cai F, Lin N, Ye J, Zheng Q, Ding G. Effects of glutamine on oxidative stress and nuclear factor-\u03baB expression in the livers of rats with nonalcoholic fatty liver disease. Exp Ther Med. 2014;7:365\u201370.","journal-title":"Exp Ther Med"},{"key":"1020_CR25","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.3945\/jn.115.215517","volume":"145","author":"C Sellmann","year":"2015","unstructured":"Sellmann C, Jin CJ, Degen C, De Bandt J-P, Bergheim I. Oral glutamine supplementation protects female mice from nonalcoholic steatohepatitis. J Nutr. 2015;145:2280\u20136.","journal-title":"J Nutr"},{"key":"1020_CR26","first-page":"p","volume":"219","author":"K Gr\u00fcngreiff","year":"2001","unstructured":"Gr\u00fcngreiff K, Lambert-Baumann J. Efficacy of l-ornithin-l-aspartate-granules in chronic liver diseases. Medizinische Welt-stuttgart. 2001;219:p.","journal-title":"Medizinische Welt-stuttgart"},{"key":"1020_CR27","first-page":"528","volume":"21","author":"L Tian","year":"2013","unstructured":"Tian L, Lu L, Tang C, Xie Y, Luo H, Tan S, et al. [Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple-dose parallel controlled clinical trial]. Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin. J Hepatol. 2013;21:528\u201332.","journal-title":"J Hepatol"},{"key":"1020_CR28","doi-asserted-by":"publisher","first-page":"S585","DOI":"10.1016\/S0168-8278(18)31432-6","volume":"68","author":"T Ermolova","year":"2018","unstructured":"Ermolova T, Ermolov S. Correction of intrahepatic microcirculation disorders by l-ornithine-l-aspartate at the chronic liver diseases patients. J Hepatol. 2018;68:S585\u20136 (abstract).","journal-title":"J Hepatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-1020-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1020-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1020-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T19:24:59Z","timestamp":1580412299000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-1020-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":28,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1020-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"31 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article is published in a special edition journal supplement wholly funded by Merz Pharmaceuticals GmbH, Frankfurt, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Prof. Ali Canbay has received a research grant from MERZ and received speaker honoraria from MERZ, Falk, Shire, and GILEAD. Jan-Peter Sowa declares that he has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}